Showing results (1-10 of 288) with videos related to

Sort By:
Pageof 29
Nature Reviews. Cancer|June 2, 2005
Pharmacokinetic variability of anticancer agentsSamir D Undevia, Gonzalo Gomez-Abuin, Mark J Ratain
European Journal of Cancer (Oxford, England : 1990)|May 26, 2009
R(+)XK469 inhibits hydroxylation of S-warfarin by CYP2C9Wei Peng Yong, Tae Won Kim, Samir D Undevia, et al.
Investigational New Drugs|August 5, 2004
Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumorsSamir D Undevia, Nicholas J Vogelzang, Ann M Mauer, et al.
Investigational New Drugs|September 15, 2010
A phase I study of continuous infusion cilengitide in patients with solid tumorsPeter H O'Donnell, Samir D Undevia, Walter M Stadler, et al.
Clinical Pharmacology and Therapeutics|November 13, 2004
A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbitalFederico Innocenti, Samir D Undevia, Jacqueline Ramírez, et al.
Investigational New Drugs|May 8, 2015
First-in-human, phase I study of elisidepsin (PM02734) administered as a 30-min or as a 3-hour intravenous infusion every three weeks in patients with advanced solid tumorsMark J Ratain, David Geary, Samir D Undevia, et al.
Ecancermedicalscience|October 5, 2020
Erratum: RENATA study-Latin American prospective experience: clinical outcome of patients treated with palbociclib in hormone receptor-positive metastatic breast cancer-real-world useFernando Petracci, Gonzalo Gomez Abuin, Alejandra Pini, et al.
Ecancermedicalscience|June 26, 2020
RENATA study-Latin American prospective experience: clinical outcome of patients treated with palbociclib in hormone receptor-positive metastatic breast cancer-real-world useFernando Petracci, Gonzalo Gomez Abuin, Alejandra Pini, et al.
Lancet Regional Health. Americas|June 30, 2025
Main challenges to cancer care in Latin America: an analysis through breast cancer lensesGonzalo Gomez-Abuin, Pablo Mandó, Guiseppe Curigliano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 24, 2009
Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatmentMichael L Maitland, Kristen E Kasza, Theodore Karrison, et al.
Pageof 29